rxdx drug：NCT01877811
NCT01877811
沒有這個頁面的資訊。。其他文章還包含有：「APhaseIIbTrialoftheVEGFR」、「AntitumorActivityofRXDX」、「DevelopmentandValidationoftheRxDx」、「Immuno-oncologicalEfficacyofRXDX」、「ImmunoGen」、「RXDXStockSkyrocketsOnPromisingResultsIn...」、「RXDX-105byF.Hoffmann」、「TheHemochronResponseRxDxheparinandprotamine...」、「ThemultikinaseinhibitorRXDX」
查看更多 離開網站
A Phase IIb Trial of the VEGFR
https://pubmed.ncbi.nlm.nih.go
The safety and antitumor activity of the multikinase RET inhibitor RXDX-105 were explored in a phase I/Ib trial. ... Neoplasms / drug therapy* ...
Antitumor Activity of RXDX
https://pubmed.ncbi.nlm.nih.go
RXDX-105 is a small molecule kinase inhibitor that potently inhibits RET. ... Neoplasms / drug therapy*; Neoplasms / genetics; Neoplasms / ...
Development and Validation of the RxDx
https://pubmed.ncbi.nlm.nih.go
The RxDx-Dementia risk index can be a useful tool to identify hypertensive and diabetic patients who are at high risk of developing dementia.
Immuno-oncological Efficacy of RXDX
https://pubmed.ncbi.nlm.nih.go
Here we characterize the small-molecule RXDX-106 as a selective and potent pan-TAM RTK inhibitor with slow dissociation kinetics and significant ...
ImmunoGen
https://www.precisionmedicineo
Takeda will develop and commercialize ImmunoGen's antibody-drug conjugate Elahere in Japan as a treatment for FRα-positive ovarian cancer.
RXDX Stock Skyrockets On Promising Results In ...
https://www.investors.com
RXDX Stock: Targeting A Ligand. Prometheus' drug is an antibody that binds to TL1A, a ligand associated with inflammation. The firm theorized ...
RXDX-105 by F. Hoffmann
https://www.pharmaceutical-tec
GlobalData's report assesses how RXDX-105's drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.
The Hemochron Response RxDx heparin and protamine ...
https://pubmed.ncbi.nlm.nih.go
The Hemochron RxDx system is widely used as a complement to traditional activated clotting time testing to optimize anticoagulation management. The system ...
The multikinase inhibitor RXDX
https://www.ncbi.nlm.nih.gov
RXDX-105 inhibits target kinases and intracellular signaling pathways ... Replicates of at least three wells were used for each drug concentration ...